Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis

被引：0
|
作者：
Hanah Kim
Mina Hur
Hee-Won Moon
Yeo-Min Yun
Salvatore Di Somma
机构：
[1] Konkuk University School of Medicine,Department of Laboratory Medicine, Konkuk University Medical Center
[2] ‘Sapienza’ University,Departments of Medical
来源：
Annals of Intensive Care | / 7卷
关键词：
Sepsis; Prognosis; Procalcitonin; Presepsin; Galectin-3; sST2;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 14 条
  • [1] Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis
    Kim, Hanah
    Hur, Mina
    Moon, Hee-Won
    Yun, Yeo-Min
    Di Somma, Salvatore
    ANNALS OF INTENSIVE CARE, 2017, 7
  • [2] Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure
    Miller, Wayne L.
    Saenger, Amy K.
    Grill, Diane E.
    Slusser, Joshua P.
    Bayes-Genis, Antoni
    Jaffe, Allan S.
    JOURNAL OF CARDIAC FAILURE, 2016, 22 (04) : 249 - 255
  • [3] An elevated level of soluble suppression of tumorigenicity 2, but not galectin-3, is associated with the presence of coronary artery disease in hypertensive patients
    Miura-Takahashi, Erika
    Tsudome, Riku
    Suematsu, Yasunori
    Tachibana, Tetsuro
    Kato, Yuta
    Kuwano, Takashi
    Sugihara, Makoto
    Tashiro, Kokei
    Shiga, Yuhei
    Kamimura, Hidetoshi
    Miura, Shin-ichiro
    HYPERTENSION RESEARCH, 2025, 48 (02) : 650 - 661
  • [4] Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial
    Serge Masson
    Pietro Caironi
    Eberhard Spanuth
    Ralf Thomae
    Mauro Panigada
    Gabriela Sangiorgi
    Roberto Fumagalli
    Tommaso Mauri
    Stefano Isgrò
    Caterina Fanizza
    Marilena Romero
    Gianni Tognoni
    Roberto Latini
    Luciano Gattinoni
    Critical Care, 18
  • [5] Multi-marker approach using C-reactive protein, procalcitonin, neutrophil CD64 index for the prognosis of sepsis in intensive care unit: a retrospective cohort study
    Na Huang
    Jing Chen
    Yu Wei
    Yongrui Liu
    Kang Yuan
    Jingli Chen
    Mingfeng He
    Nan Liu
    BMC Infectious Diseases, 22
  • [6] Multi-marker approach using C-reactive protein, procalcitonin, neutrophil CD64 index for the prognosis of sepsis in intensive care unit: a retrospective cohort study
    Huang, Na
    Chen, Jing
    Wei, Yu
    Liu, Yongrui
    Yuan, Kang
    Chen, Jingli
    He, Mingfeng
    Liu, Nan
    BMC INFECTIOUS DISEASES, 2022, 22 (01)
  • [7] Galectin-3 and suppression of tumorigenicity 2: Two emerging cardiac biomarkers that may be predictors of cardiac fibrosis development in sport
    Le Goff, Caroline
    EXPERIMENTAL PHYSIOLOGY, 2023, 108 (10) : 1257 - 1258
  • [8] Usefulness of Enhanced Liver Fibrosis, Glycosylation Isomer of Mac-2 Binding Protein, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for Assessing Liver Fibrosis in Chronic Liver Diseases
    Moon, Hee-Won
    Park, Mikyoung
    Hur, Mina
    Kim, Hanah
    Choe, Won Hyeok
    Yun, Yeo-Min
    ANNALS OF LABORATORY MEDICINE, 2018, 38 (04) : 331 - +
  • [9] Development of heart failure risk prediction models based on a multi-marker approach using random forest algorithms
    Yuan, Hui
    Fan, Xue-Song
    Jin, Yang
    He, Jian-Xun
    Gui, Yuan
    Song, Li-Ying
    Song, Yang
    Sun, Qi
    Chen, Wei
    CHINESE MEDICAL JOURNAL, 2019, 132 (07) : 819 - 826
  • [10] Interleukin 33, soluble suppression of tumorigenicity 2, interleukin 27, and galectin 3 as predictors for outcome in patients admitted to intensive care units
    Eric, Stevan
    Zaric, Radica Zivkovic
    Jevdjic, Jasna
    Drakulic, Svetlana Miletic
    Stanojevic, Ivan
    Vojvodic, Danilo
    Arsenijevic, Petar
    Stojanovic, Bojan
    Jakovljevic, Stefan
    Markovic, Nenad
    Zaric, Milan
    Canovic, Petar
    Nesic, Jelena
    Zornic, Nenad
    OPEN MEDICINE, 2023, 18 (01):
12